Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE II CLINICAL TRIAL OF KN026 COMBINED WITH PALBOCICLIB AND FULVESTRANT FOR THE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER 2022-05-26
GRANT OF AWARD SHARES UNDER THE RESTRICTED SHARE AWARD SCHEME 2022-05-20
FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 10, 2022 2022-05-10
NOTICE OF ANNUAL GENERAL MEETING 2022-05-10
(1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES; (2) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (3) PROPOSED RE-APPOINTMENT OF AUDITORS; AND (4) NOTICE OF ANNUAL GENERAL MEETING 2022-05-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2022 2022-05-06
GRANT OF SHARE OPTIONS 2022-04-25
VOLUNTARY ANNOUNCEMENT - UPDATES ON CLINICAL DATA OF KN046 IN COMBINATION WITH KN026 FOR THE TREATMENT OF HER2-POSITIVE SOLID CANCER FOR PRESENTATION AT 2022 AACR ANNUAL MEETING 2022-04-11
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2022 2022-04-07
VOLUNTARY ANNOUNCEMENT - THE FIRST INTERIM ANALYSIS OF A PHASE III CLINICAL TRIAL OF KN046 SUCCESSFULLY REACHED PRESPECIFIED PFS ENDPOINT 2022-03-31

12 13 14 15 16 17 18